Last reviewed · How we verify
GR205171
At a glance
| Generic name | GR205171 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder (PHASE2)
- A Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects (PHASE1)
- A Study With GW597599 And GR205171: Potential New Drugs For The Treatment Of Primary Insomnia (PHASE2)
- First Time in Human Study (FTIH) With Positron Emission Tomography (PET) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GR205171 CI brief — competitive landscape report
- GR205171 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI